MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ligand Pharmaceuticals Inc

Open

SectorGezondheidszorg

104.84 -1.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

103.99

Max

109.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-24M

-31M

Verkoop

-9M

43M

K/W

Sectorgemiddelde

47.016

57.333

EPS

1.27

Winstmarge

-72.615

Werknemers

68

EBITDA

-33M

-30M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+40.57% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-42M

2B

Vorige openingsprijs

106.38

Vorige sluitingsprijs

104.84

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Ligand Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 23:54 UTC

Populaire aandelen

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr 2025, 23:51 UTC

Marktinformatie

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 apr 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr 2025, 23:37 UTC

Top Nieuws

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr 2025, 23:36 UTC

Top Nieuws

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr 2025, 23:13 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr 2025, 23:09 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr 2025, 23:02 UTC

Acquisities, Fusies, Overnames

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 22:48 UTC

Top Nieuws

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr 2025, 22:47 UTC

Marktinformatie

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr 2025, 22:38 UTC

Marktinformatie
Winsten

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr 2025, 22:24 UTC

Winsten

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr 2025, 22:24 UTC

Marktinformatie
Winsten

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr 2025, 22:23 UTC

Winsten

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

24 apr 2025, 22:11 UTC

Marktinformatie
Winsten

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr 2025, 22:09 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr 2025, 22:00 UTC

Marktinformatie
Winsten

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr 2025, 21:39 UTC

Top Nieuws

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr 2025, 21:23 UTC

Top Nieuws
Winsten

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr 2025, 21:04 UTC

Winsten

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr 2025, 21:03 UTC

Winsten

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr 2025, 21:02 UTC

Winsten

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Peer Vergelijking

Prijswijziging

Ligand Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

40.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 148.67 USD  40.57%

Hoogste 160 USD

Laagste 135 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ligand Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technische score

By Trading Central

104.86 / 111.39Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.